Insilico Medicine plans joint venture with Pudong Construction to launch RMB 1.01 billion biopharma fund

PUBT · 2d ago
Insilico Medicine plans joint venture with Pudong Construction to launch RMB 1.01 billion biopharma fund
  • Insilico Medicine Cayman Topco weighed joining Pudong Construction, Shanghai Pudong Development Group in a JV to set up an investment fund.
  • Planned JV: RMB 3 million injection via Insilico Shanghai Investment for a 60% stake in RMB 5 million registered capital.
  • Proposed fund commitment: RMB 302.5 million via Insilico Medicine Ltd. and the JV, alongside Value Partners’ PE unit.
  • Target fund size: RMB 1.01 billion, focused on biopharma investments.
  • No definitive agreements signed; transaction may proceed as a discloseable transaction under Hong Kong listing rules.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260818-12288769), on August 18, 2026, and is solely responsible for the information contained therein.